Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis. by Kitt, H et al.
CASE REPORT Open Access
Two case reports of the successful
eradication of new isolates of Burkholderia
cepacia complex in children with cystic
fibrosis
H. Kitt1, W. Lenney1 and F. J. Gilchrist1,2*
Abstract
Background: Chronic infection with Burkholderia cepacia complex (BCC) has a detrimental effect on morbidity and
mortality for patients with cystic fibrosis (CF). It is therefore logical to attempt to eradicate new isolates however
there is a paucity of information to guide treatment. We report the successful eradication of new isolates of BCC in
two children with CF.
Case presentation: Burkholderia cepacia was successfully eradicated in a 14 year old boy with CF and Burkholderia
gladioli was successfully eradicated in a six year old girl with CF. In both children two weeks of intravenous (IV)
tobramycin, ceftazidime and temocillin were used followed by three months of inhaled tobramycin.
Bronchoalveolar lavage samples taken during flexible bronchoscopy were used prior to treatment to exclude
spontaneous clearance as well as after treatment to confirm eradication.
Conclusions: New isolates of BCC can be successfully eradicated in children with CF. More research is urgently
required in this area to identify the best treatment regimen for BCC eradication.
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Background
Cystic fibrosis (CF) is the commonest life shortening,
inherited disease in the Caucasian population. It is char-
acterised by recurrent lower respiratory infections, in-
flammation and lung damage. Burkholderia cepacia
complex (BCC) refers to a group of at least 17 closely re-
lated bacterial species (formerly called genomovars) that
can cause pulmonary infection in patients with cystic fi-
brosis (CF) [1–3]. These Gram-negative organisms are
inherently resistant to Colistin and can survive for pro-
longed periods in moist environments such as water and
soil [1]. In patients with CF, new BCC infection can clear
spontaneously or require eradication with a combination
of antibiotics. If new infection is not cleared, chronic in-
fection develops. Chronic BCC infection is associated
with a more rapid decline in lung function [4], increased
requirements for intravenous antibiotics [5], increased
outpatient attendance and increased mortality [6]. Pa-
tient to patient spread of epidemic strains of Burkhol-
deria cenocepacia (such as ET12) was identified at a
number of CF centres in the early 1990’s [7]. This had a
catastrophic effect on the CF population due to its asso-
ciation with Cepacia Syndrome. This is an acute, necro-
tising pneumonia with an almost universal fatal outcome
[8]. The presence of Burkholderia cenocepacia remains a
contraindication to lung transplantation at most CF
transplantation centres due its association with poor
outcomes [9]. The widespread segregation of CF clinics
has been successful in reducing the overall prevalence of
chronic BCC infection in the UK to 3 % [10]. It is pre-
dominantly seen in adult patients [10]. The success of
segregation means that most new BCC infections are
now acquired from the environment rather than from
other patients [11].
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Despite a wealth of knowledge on the adverse long-
term effects of BCC infection, there is lack of reliable
evidence on which to base management decisions for CF
patients with new or chronic BCC infection [12, 13]. An
in-vitro study suggest that triple-antibiotic combinations
are more likely than double and single antibiotic combi-
nations to be bactericidal against BCC [14]. Despite
this, a Cochrane Systematic Review failed to identify
a single randomised study investigating BCC eradica-
tion and concluded that “without further comprehen-
sive studies it is difficult to draw conclusions about a
safe and effective management strategy for BCC
eradication in CF” [13]. A review of practice in UK
CF Centres revealed that despite this lack of evidence,
most attempt to eradicate new isolates of BCC. The
treatment regimens vary widely and reported success
was limited (37 %) [15]. The published evidence is
limited to a few small case series. Some of these use
a combination of intravenous and nebulised antibi-
otics [16], others use a combination of nebulised anti-
biotics [17] and others a single nebulised antibiotic
[18]. We report two children in whom new isolates of
BCC have been successfully eradicated using the same
combination of intravenous (IV) and inhaled antibi-
otics. These are the only two cases of attempted BCC
eradication at our centre in the last eight years.
Case presentations
Child 1
A 14 year old boy with CF (homozygous Phe508del) pre-
sented with a 2 week history of a wet cough productive
of green sputum. His lung function remained stable
(FEV1 90 %) and clinical examination was unremarkable.
He was known to be chronically infected with Staphylo-
coccus aureus but was free from Pseudomonas aerugi-
nosa (last isolate 34 months previously) and had never
grown BCC. His treatment included nebulised dornase
alfa but no nebulised antibiotics. The sputum culture
from this presentation isolated BCC, Staphylococcus
aureus, and Haemophilus influenza. Table 1 shows the
antibiotic sensitivities. The BCC isolate was sent to the
National Reference Laboratory where recA sequencing
confirmed its identity as Burkholderia cepacia. The anti-
biotic sensitivities are given in Table 1. Five weeks after
the first isolate, flexible bronchoscopy with single aliquot
bronchoalveolar lavage samples (FB-BAL) from six lobes
(including the lingula lobe) was performed to see if the
organism had spontaneously cleared. BCC was isolated
from all the sampled lobes. A 2 week eradication regi-
men was planned using intravenous (IV) tobramycin
(10 mg/kg once daily), ceftazidime (50 mg/kg three
times daily), and temocillin (2 g twice daily) followed by
3 months of nebulised meropenem (250 mg twice daily).
The IV antibiotics were administered in hospital without
any problems. Trough serum tobramycin concentrations
were <1 mg/L when measured on day 2 and day 8 of
treatment. Renal and liver functions were also within
normal limits. Unfortunately, the patient could not toler-
ate the nebulised meropenem due to the taste. He was
therefore prescribed 3 months of inhaled tobramycin.
The possibility of using either a nebulised or a dry pow-
der (TIP) formulation was discussed with the patient
who chose the latter. The patient passed his trial of TIP
and treatment was commenced (112 mg twice daily) the
day after his IV antibiotics had finished. The family re-
ported excellent adherence with the 3 months of treat-
ment. All subsequent microbiology samples have been
negative for BCC. These have included four sputum cul-
tures whilst still on TIP, FB-BAL samples taken 1 month
after the end of the eradication course and three subse-
quent cough swabs. The last sample was 13 months after
the first BCC isolate.
Child 2
Four weeks after the above child first isolated BCC, a
6 year old girl with CF (homozygous Phe508del) also
isolated BCC from a cough swab after a four week his-
tory of cough and shortness of breath. She had isolated
Pseudomonas aeruginosa on two previous occasions
(latest 20 months ago) and was receiving nebulised dor-
nase alpha but not nebulised antibiotics. The BCC iso-
late was sent to the National Reference Laboratory
where gryB cluster analysis confirmed its identity as
Burkholderia gladioli. The antibiotic sensitivities are
given in Table 1. FB-BAL was performed 4 weeks after
the positive culture to check if it had spontaneously
cleared but BCC was isolated from all six sampled lobes.
She completed 2 weeks of IV tobramycin (10 mg/kg
once daily), ceftazadime (50 mg/kg three times daily)
and temocillin (1 g twice daily). Trough serum tobra-
mycin concentrations were <1 mg/L when measured on
day 2 and day 8 of treatment. Renal and liver function
were also within normal limits. As she had previously
struggled to tolerate the taste of nebulised treatments
Table 1 Antibiotic sensitivities of the two BCC isolates
Ceftaz Tazocin Cipro Gent Tobra Amikacin Mero Colistin Aztreo Temo
Child 1 S S I R R R S R I S
Child 2 S R I I I R S R R S
Ceftaz ceftazidime; Cipro ciprofloxacin; Gent gentamicin; Tobra tobramycin; Mero meropenem; Aztreo aztreonam; Temo temocillin; S sensitive; I intermediate;
R resistant
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we did not try nebulised meropenem and went straight
for 3 months of nebulised tobramycin (300 mg twice
daily). This was started on the day the IV antibiotics fin-
ished. She tolerated this well and the family reported ex-
cellent adherence. During this time her lung function
and clinical status remained stable. All subsequent
microbiology samples have been negative for BCC. This
has included four cough swabs cultures whilst still on
nebulised tobramycin, FB-BAL samples taken 1 month
after the eradication course finished and six subsequent
cough swabs. The last sample was 12 months post first
BCC isolate.
Discussion
We report two children with CF in whom new isolates of
BCC were successfully eradicated using the same combin-
ation of intravenous and inhaled antibiotics. There is a
paucity of evidence to inform practice on the eradication
of BCC and we believe that these are the first two isolates
successfully treated and reported in children. A Cochrane
review concluded that there is “an extreme lack of evi-
dence in this area of treatment management for people
with cystic fibrosis” [13]. Although this report adds to the
available evidence there is still an urgent need for multi-
centre randomised controlled trials to investigate anti-
biotic regimens for the eradication of BCC.
The BCC isolates in these children were identified as
Burkholderia cepacia and Burkholderia gladioli. The
progression of Burkholderia cepacia infection and its det-
rimental effect on morbidity and mortality is well estab-
lished [11]. The clinical significance of Burkholderia
gladioli infection in patients with CF is slightly more con-
troversial as infections can be transient and prevalence of
chronic infection is relatively low [19]. However, there is
evidence that if chronic infection does develop there is as-
sociated morbidity both pre and post-transplant [20, 21].
In these children we checked for spontaneous clearance
by performing FB-BAL four/five weeks after the initial iso-
late. In both, BCC was identified in all six of the sampled
lobes excluding this possibility. We were equally thorough
in our assessment of the success of eradication. This in-
cluded FB-BAL one month after eradication had com-
pleted in addition to regular respiratory microbiology
samples during and after treatment.
Conclusions
In conclusion, new isolates of BCC can be eradicated in
children with CF. This report identifies one possible
eradication regimen using three IV antibiotics and one
nebulised antibiotic. More research is required to estab-
lish which eradication regimen is the best for new iso-
lates of BCC.
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